Clinical Trial Update: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) [Phase 2]

View source ↗

Summary

Phase II study evaluating re-treatment with ruxolitinib in patients with primary myelofibrosis after interruption due to loss of response or adverse events; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jakavi (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2016-02-10